Abstract
Objective: The purpose of this study is to evaluate obstetric outcomes in pregnant women who received second-generation long-acting injectable antipsychotics (LAIAs) compared to a control group who received second-generation oral antipsychotics.
Methods: This was a retrospective study utilizing a global cohort of 148 health care organizations grouped into a network within the TriNetX database. Pregnant patients of any trimester were grouped into 2 cohorts: (1) exposure to long-acting aripiprazole, risperidone, paliperidone, or olanzapine (n=2,082) and (2) exposure to the corresponding oral formulations (n=31,376) and propensity matched. The primary outcome was the occurrence of one of the following obstetric complications: gestational diabetes, preeclampsia, eclampsia, or a newly diagnosed hypertensive disorder. Cesarean section rates were also assessed.
Results: After propensity matching, each cohort yielded 2,025 patients. No intergroup differences were observed in the composite primary end point, performed postmatching (odds ratio 0.95; 95% CI, 0.76–1.18; P=.61). No difference in rates of cesarean section was observed.
Conclusion: Similar rates of gestational diabetes, eclampsia, preeclampsia, and maternal hypertensive disorders were observed in women receiving long-acting injectable and oral second-generation antipsychotics.
J Clin Psychiatry 2026;87(1):25m16033
Author affiliations are listed at the end of this article.
Members Only Content
This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.
References (30)
- American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association Publishing; 2020.
- Tosato S, Albert U, Tomassi S, et al. A systematized review of atypical antipsychotics in pregnant women: balancing between risks of untreated illness and risks of drug-related adverse effects. J Clin Psychiatry. 2017;78(5):e477–e489. PubMed CrossRef
- ACOG Committee on Practice Bulletins—Obstetrics. Use of psychiatric medications during pregnancy and lactation. Clin Manag Guidel Obstetrician-Gynecologists. 2008;92(87):1001–1020.
- Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. PubMed CrossRef
- Swetlik C, Cohen LS, Kobylski LA, et al. Effects of prenatal exposure to second-generation antipsychotics on development and behavior among preschool-aged children: preliminary results from the National Pregnancy Registry for Psychiatric Medications. J Clin Psychiatry. 2024;85(1):23m14965. PubMed CrossRef
- Panchaud A, Hernandez-Diaz S, Freeman MP, et al. Use of atypical antipsychotics in pregnancy and maternal gestational diabetes. J Psychiatr Res. 2017;95:84–90. PubMed CrossRef
- Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175(6):564–574. PubMed CrossRef
- Ellfolk M, Leinonen MK, Gissler M, et al. Second-generation antipsychotics and pregnancy complications. Eur J Clin Pharmacol. 2020;76(1):107–115. PubMed CrossRef
- ACOG Committee on Practice Bulletins—Obstetrics. Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;92:1262–1288.
- Correll CU. Long-acting injectable antipsychotics for patients with first-episode and early-phase schizophrenia: still not considered often enough. CNS Spectr. 2025;30(1):e66. PubMed CrossRef
- Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619. PubMed CrossRef
- Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. PubMed CrossRef
- Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709–3716. PubMed CrossRef
- Pejčić AV, Stefanović SM, Milosavljević MN, et al. Outcomes of long-acting injectable antipsychotics use in pregnancy: a literature review. World J Psychiatry. 2024;14(4):582–599. PubMed CrossRef
- Nguyen T, Frayne J, Watson S, et al. Long-acting injectable antipsychotic treatment during pregnancy: outcomes for women at a tertiary maternity hospital. Psychiatry Res. 2022;313:114614. PubMed CrossRef
- Uhlig K, Menon V, Schmid CH. Recommendations for reporting of clinical research studies. Am J Kidney Dis. 2007;49(1):3–7. PubMed CrossRef
- First-and Second-Trimester Pregnancy Loss. Williams Obstetrics, 26e AccessMedicine. McGraw Hill Medical. Accessed November 16, 2025. https://accessmedicine.mhmedical.com/content.aspx?sectionid=263815963&bookid=2977#263815972
- Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–1638. PubMed CrossRef
- Wesseloo R, Kamperman AM, Munk-Olsen T, et al. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117–127. PubMed CrossRef
- Huybrechts KF, Straub L, Karlsson P, et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry. 2023;80(2):156–166. PubMed CrossRef
- Straub L, Hernández-Díaz S, Bateman BT, et al. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med. 2022;182(5):522–533. PubMed CrossRef
- Liu X, Kolding L, Momen N, et al. Maternal antipsychotic use during pregnancy and congenital malformations. Am J Obstet Gynecol MFM. 2023;5(6):100950. PubMed CrossRef
- Anderson KN, Ailes EC, Lind JN, et al. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011. Schizophr Res. 2020;215:81–88. PubMed CrossRef
- Wang E, Liu Y, Wang Y, et al. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs. 2025;39(1):1–22. PubMed CrossRef
- Uguz F. Antipsychotic use during pregnancy and the risk of gestational diabetes mellitus: a systematic review. J Clin Psychopharmacol. 2019;39(2):162–167. PubMed CrossRef
- Kananen A, Bernhardsen GP, Lehto SM, et al. Quetiapine and other antipsychotic medications during pregnancy: a 15-year follow-up of a university hospital birth register. Nord J Psychiatry. 2023;77(7):651–660. PubMed CrossRef
- Eleftheriou G, Butera R, Sangiovanni A, et al. Long-acting injectable antipsychotic treatment during pregnancy: a case series. Int J Environ Res Public Health. 2023;20(4):3080. PubMed CrossRef
- O’Sullivan DL, Byatt N, Dossett EC. Long-acting injectable antipsychotic medications in pregnancy: a review. J Acad Consult Liaison Psychiatry. 2022;63(1):53–60. PubMed
- Sheehan JJ, Reilly KR, Fu D-J, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7–8):17–23. PubMed
- Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(suppl 16):18–23. PubMed
